Use of a decision-analytic model in a health technology assessment: beyond measuring value for money by unknown
Israel Journal of
Health Policy Research
Kim Israel Journal of Health Policy Research 2013, 2:15
http://www.ijhpr.org/content/2/1/15COMMENTARY Open AccessUse of a decision-analytic model in a health
technology assessment: beyond measuring
value for money
Sun-Young KimAbstract
The well-designed, model-based cost-utility analysis by Ginsberg and colleagues provides useful information on the
value for money of universal GBS screening in Israel. An extended application of the model-based approach used in
the study could provide policymakers additional practical information on the budget impact of a potential universal
GBS screening program. Such an approach could also be used to guide future research priorities in the prevention
of GBS in Israel, by measuring the value of seeking further information to reduce the uncertainty in the cost-effectiveness
of universal GBS screening.
This is a commentary on http://www.ijhpr.org/content/2/1/6.Policymakers are confronted with a variety of policy
questions in making resource allocation decisions among
health interventions that target diverse groups of patients
or subpopulations. These questions range from efficiency
to equity, and often involve the consideration of a society’s
core values. Due to the ever-increasing economic burden
of health care globally and the availability of new (but
highly expensive) technologies, one of the most frequently
asked questions by policymakers in regards to health
interventions is whether they provide good value for
money relative to alternative interventions. In the previous
issue, the well-designed, model-based cost-utility analysis
conducted by Ginsberg and his colleagues [1] provides an
example of studies that can answer such a question.
In the study, Ginsberg and colleagues attempt to address
the question of whether Israel should expand its coverage
of preventive screening against group B streptococcal
(GBS) infection to all pregnant women [1]. In doing
so, they take the framework of cost-utility analysis (or
cost-effectiveness analysis, which is often interchangeably
used, but encompasses both types of analyses with and
without utility assessment of health outcomes). They
then assess the potential health and economic impact of
universal screening (taking a vaginal-rector culture forCorrespondence: sun-young.kim@uth.tmc.edu
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reproduction in any medium, provided the orGBS screening from all pregnant women at 35–37 weeks
of gestation) compared to the current practice in Israel of
risk-based screening (performing a culture screening
in mothers with known risk factors only) in terms of
additional costs per quality-adjusted life year gained.
In conducting a health technology assessment, it is
crucial to choose the right approach and methods
according to the nature of the questions being asked and
policy goals. It would be ideal if well-designed, rigorously
conducted clinical trials could provide data on both costs
and effectiveness of an intervention under consideration.
Unfortunately, for multiple reasons (e.g., prohibitively high
costs or ethical concerns), such rigorous primary research
is not feasible for many health technology assessment
studies [2]. When there are not enough high quality
datasets with which to assess the costs and effectiveness
profiles of an intervention, a decision-analytic simulation
model can serve as a useful tool to synthesize evidence
and imperfect information [3]. More and more recent
economic evaluation studies or health technology
assessments take a model-based approach, supplementing
the results obtained from empirical studies. There are
various types of models, ranging from a simple, less costly,
transparent model to a complex, costly, but more
flexible one [4]. When conducting a model-based
study, it is also crucial to choose the right type of
decision-analytic model, taking into account the nature ofis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Kim Israel Journal of Health Policy Research 2013, 2:15 Page 2 of 3
http://www.ijhpr.org/content/2/1/15the disease being simulated and the trade-offs among
different types of models [5].
In conducting an ex ante evaluation of universal GBS
screening, Ginsberg and colleagues take a model-based
approach [1]. They develop a spreadsheet model (implicitly
based on a decision-tree structure) and synthesize the best
available data into the model to project the costs and
health outcomes of the two alternative screening strategies
for preventing the burden of GBS disease in Israel. Their
findings suggest that universal GBS screening would offset
a majority of the program costs for expanding its coverage
by effectively reducing the burden of GBS disease and thus
saving medical costs for treating GBS disease in infants.
A model-based study inevitably requires assumptions
about the costs, effectiveness of interventions, and
disease burden [3,6]. Accordingly, the quality of a health
technology assessment using a model is only as good as
the quality of the assumptions and data synthesized into
the model that provides the information.
Despite these inherent limitations, a model-based
approach has several strengths [3,6]. In this light, the
model-based approach used in Ginsberg et al.’s study
has the potential to provide policymakers additional
practical information beyond the cost-effectiveness
profile of universal GBS screening that they might find
useful in making decisions about whether to adopt a
universal screening program.
First of all, a decision-analytic model can be set up
(by being assigned probability distributions to model
parameters) so that it can conduct a probabilistic analysis
based on Monte Carlo simulations. Such a probabilistic
decision-analytic model can then be used to perform
a more comprehensive type of sensitivity analysis (e.g.,
a probabilistic sensitivity analysis that varies all key
parameters at the same time). In Ginsberg et al.’s study,
the deterministic one- and two-way sensitivity analysis
results note that, while the base-case results are very
cost-effective, the results are very sensitive to some of
the key parameters (such as GBS prevalence, the proportion
of meningitis cases leading to long-term disabilities, and
the probability of intrapartum antibiotic prophylaxis-related
anaphylaxis). This may warrant a more comprehensive
sensitivity analysis that varies all key variables at the
same time. Ginsberg et al.’s study could use their model
to conduct a probabilistic sensitivity analysis by assigning
distributions to key parameters and conducting a second-
order Monte Carlo simulation in which all key parameter
values are sampled from the distributions. The simulated
outcomes then can be summarized in some form of visual
presentation, in order to provide more accessible and
comprehensive information on the uncertainties about
the outcomes of a universal screening. For example, a
cost-effectiveness acceptability curve can show the
probability that universal GBS screening would becost-effective relative to the current risk-based screening
at varying levels of threshold cost-effectiveness ratio [7].
Further, once a decision-analytic model is set up for a
probabilistic analysis, the same probabilistic model can
be used to conduct another type of uncertainty analysis,
a value of information (VOI) analysis. VOI analysis is an
analytic framework that can calculate the value of seeking
further information to support a decision [8]. For example,
given the uncertainties surrounding some key parameters
in Ginsberg et al.’s study, policymakers may want to know
whether further research is needed to reduce uncertainty
about the parameters and whether better information on
the parameters would lead to a different conclusion about
the optimal strategy for preventing GBS disease in Israel.
In this case, a probabilistic decision simulation model
can be used to perform a VOI analysis and can provide
the value of reducing the uncertainty associated with the
choice of universal GBS screening through additional
research.
Another useful application of a model-based approach
is that the same decision-analytic model can be used to
project the budget impact of the potential adoption of a
health intervention under consideration, which might
provide additional practical information for policymakers
[9]. The budget impact analysis is performed from
the perspective of a payer and provides the financial
requirements (by considering financial costs only,
not economic costs) for adopting a new intervention over
a typical period of 1–5 years, so that payers can compare
the amount of financing required with the size of the
available budget. Given Israel’s unique system of choosing
health interventions under an annual budget constraint,
policymakers might find this type of additional information
particularly useful.
Does the study by Ginsberg and colleagues answer their
stated question “Should Israel screen all mothers-to-be to
prevent early-onset of neonatal group B streptococcal
disease?” Assuming that the question implicitly focuses on
a value for money (that is, based on cost-effectiveness
grounds only), the answer may be yes. However, it is
important to note that cost-utility analysis or cost-
effectiveness analysis on their own cannot answer all
priority-setting questions [10], and thus cannot conclu-
sively answer the question of whether the decision
makers would be best to adopt a universal screening
strategy based on the findings of the study. Future
health technology assessments should be conducted,
keeping in mind this inherent restriction on the types of
questions the cost-utility analysis framework can answer.
Thus, by developing sophisticated decision-analytic methods
(including the extended use of a decision-analytic model),
researchers are positioned to best inform policymakers
on the important types of questions to which their methods
are suited.
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